Difference between skin toxicities in erlotinib (E) and gefitinib (G) in the treatment of advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Defferrari, C. [1 ]
Loprevite, M. [1 ]
Brianti, A. [1 ]
Catania, G. [1 ]
Grossi, F. [1 ]
Pronzato, P. [1 ]
机构：
[1] Natl Inst Canc Res, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18187
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Skin toxicities difference between erlotinib (E) and gefitinib (G) in the treatment of advanced non-small-cell lung cancer (NSCLC)
    Brianti, A.
    Defferrari, C.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Grossi, F.
    Pronzato, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 28 - 28
  • [2] DIFFERENCE IN SKIN TOXICITY INCIDENCE BETWEEN ERLOTINIB (E) AND GEFITINIB (G) IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Grossi, F.
    Defferrari, C.
    Brianti, A.
    Dal Bello, M. G.
    Catania, G.
    Pronzato, P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 106 - 107
  • [3] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    [J]. DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [5] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [6] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 395 - 395
  • [7] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Defferrari, C.
    Brianti, A.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    Grossi, F.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 24 - 24
  • [8] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    [J]. LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [9] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [10] Cutaneous toxicity in erlotinib treatment for advanced non-small cell lung cancer (NSCLC)
    Bernabee, R.
    Cobo, M.
    Barneto, I.
    Valdivia, J.
    Fernandez, I.
    Rueda, A.
    Villatoro, R.
    de la Curz, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345